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the absence of the classical complement pathway. T cells 
and natural killer cells are relevant for intracortical type 2 
but dispensable for subpial type 3 lesions, whereas  CCR2+ 
monocytes are required for both. Depleting  CCR2+ mono-
cytes in marmoset monkeys with experimental autoimmune 
encephalomyelitis using a novel humanized CCR2 target-
ing antibody translates into significantly less cortical demy-
elination and disease severity. We conclude that biologics 
depleting  CCR2+ monocytes might be attractive candidates 
for preventing cortical lesion formation and ameliorating 
disease progression in MS.
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Abstract Cortical demyelination is a widely recognized 
hallmark of multiple sclerosis (MS) and correlate of dis-
ease progression and cognitive decline. The pathomecha-
nisms initiating and driving gray matter damage are only 
incompletely understood. Here, we determined the infiltrat-
ing leukocyte subpopulations in 26 cortical demyelinated 
lesions of biopsied MS patients and assessed their contri-
bution to cortical lesion formation in a newly developed 
mouse model. We find that conformation-specific anti-mye-
lin antibodies contribute to cortical demyelination even in 
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The cortex is a major predilection site for demyelina-
tion in multiple sclerosis (MS) [18]. Cortical pathology 
is increasingly recognized in all MS phenotypes by non-
conventional ultra-high field magnetic resonance imaging 
(MRI) from the earliest disease stages on, including pedi-
atric-onset MS [1]. The presence of gray matter damage 
has been associated with long-term physical and cogni-
tive impairment [11] and has early prognostic relevance 
for the conversion to clinically definite MS [15]. Also, 
MRI studies have consistently demonstrated that gray 
matter atrophy reflects disability progression better than 
white matter atrophy or T2 lesion load, suggesting that 
cortical pathology plays a pivotal role in disease progres-
sion [12].
Three cortical lesion types have been distinguished 
in studies of MS pathology according to topography [7, 
41]: Leukocortical lesions (type 1) encompassing deep 
cortical areas and subcortical white matter, intracortical 
lesions centered on intracortical microvessels (type 2) 
and subpial lesions extending from the pia mater into the 
superficial cortical layers (type 3). Subpial type 3 lesions 
are the most frequent and extensive cortical lesion type 
and more specific to MS than white matter lesions [36]. 
In postmortem brain tissue of patients with chronic MS, 
cortical demyelinated lesions in general and subpial cor-
tical demyelinated lesions in particular are less inflam-
matory than demyelinated white matter lesions [3, 7, 28]. 
Thus, degenerative processes have been proposed to pre-
vail in cortical pathology. This view has been challenged 
by biopsy studies of cortical demyelinated lesions, which 
were highly inflammatory [32] and by animal studies 
demonstrating the rapid resolution of cortical inflamma-
tion [35]. In addition, expression signatures characteristic 
of innate and adaptive immune activation can be found in 
cortical demyelinated lesions at autopsy [16] and subpial 
cortical demyelination was often associated with menin-
geal inflammation [21]. In line, a recent imaging study 
demonstrated focal, long-lasting leptomeningeal contrast 
enhancements in postcontrast T2 weighted fluid-attenu-
ated inversion recovery (FLAIR) MRI in MS [2]. Patho-
genetically, meningeal inflammatory cells might release 
myelino- and neurotoxic soluble mediators, which diffuse 
into the superficial gray matter, contributing to demyeli-
nation and the reported gradient of neuronal damage [33].
Although there is little doubt about the causative 
role of inflammatory processes for cortical demyelina-
tion and ensuing neuroaxonal damage, surprisingly little 
quantitative data is available on immune cell subpopu-
lations in cortical demyelinated lesions and meningeal 
infiltrates. Even less is known about the cellular and 
humoral mediators contributing to cortical demyelina-
tion. Macrophages and T cells were reported to outnum-
ber B cells in meningeal inflammation in progressive MS 
patients [21] and complement deposits were inconsist-
ently detected in human autopsy specimens [9, 52]. In 
the present work, we set out to study quantitatively adap-
tive and innate immune cell populations in a cohort of 
patients with early cortical demyelination. Furthermore, 
we employed immune cell depletion and genetic manipu-
lations in a newly developed experimental mouse model 
of cortical demyelination to define the immune effector 
mechanisms operating in cortical demyelination in vivo. 
We finally translated our findings into a novel, biological 
therapy against cortical pathology in MS.
Materials and methods
Patients
We screened a cohort of 740 archival CNS biopsies of 
patients diagnosed with inflammatory demyelinating dis-
ease between 1999 and 2016 for the presence of cortical 
demyelination. Biopsies were performed for diagnostic rea-
sons to exclude tumor or infection and targeted MRI-defined 
white matter lesions (Table S1). The study was approved 
by the ethical review committee of the University Medical 
Center Göttingen (#19/09/10). All biopsies were stained 
with HE and LFB/PAS and Bielschowsky silver impreg-
nated. Immunohistochemistry (IHC) was performed with 
antibodies against myelin, oligodendrocytes, adaptive and 
innate immune cells, neurons and axons, astrocytes, includ-
ing AQP4, JC virus and Ki-67. Biopsies with cortical demy-
elination were in addition stained with antibodies against 
CCR2 and double-labelled for CCR2/CD14 and CCR2/
KiM1P to identify recently invaded monocytes and tissue 
macrophages, and GrB/CD3 to identify natural killer (NK) 
cells. Demyelinating lesion activity was determined accord-
ing to Brück et al. [10] and Kuhlmann et al. [27]. Lesions 
without myelin-laden macrophages were staged according 
to Schirmer et al. [47]. Primary antibodies used for IHC of 
human MS biopsies are listed in Table S2 and exemplary 
IHC of tonsillar tissue with antibodies against CD3, CD4, 
CD8, CD20 and CD138 is provided as Supplemental Fig. 6.
135 biopsies (18%) contained cortical tissue in addi-
tion to subcortical white matter (Figure S1). Of those, 26 
patients (19%) showed cortical demyelination identified 
by myelin immunohistochemistry. All but two patients 
also harbored subcortical white matter for analysis. 20/26 
patients showed white matter demyelination in addition to 
cortical demyelination. Intracortical (type 2) lesions were 
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exceedingly rare in this cohort, and leukocortical (type 1) 
lesions were not included in the present study.
The median age of the patients at biopsy was 41 (inter-
quartile range, 30–49), the median time to biopsy was 
2 months (interquartile range, 0.5–24) and the female to 
male ratio was 2.3. 10/26 patients had seizures or were 
diagnosed with symptomatic epilepsy and 8/26 patients 
presented with moderate to severe neuropsychiatric symp-
toms (confusion, cognitive impairment, depression; Table 
S1). The clinical diagnosis at the time of biopsy was CIS in 
16, RRMS in 8 and SPMS in 2 cases.
Animals
C57BL/6J mice were obtained from Charles River Labora-
tories (Charles River). 2D2 mice  (TCRMOG) [6], Th/+mice 
 (IgGMOG, kindly provided by Tobias Litzenburger, Antonio 
Iglesias and Hartmut Wekerle [31]), OSE double trans-
genic mice  (TCRMOG × IgGMOG) [5, 26],  RAG1−/− mice 
[37],  RAG2−/− γc−/−,  RAG1−/− γc-/-,  C1q−/− (kindly 
provided by Marina Botto [8]) and OT-II [4] mice were 
bred at the animal facility of the University of Göttingen 
under SPF conditions. Th/+CCR2−/−, Th/+C1q−/− and 
Th/+CD59a−/− mice were generated by crossbreeding 
 CCR2−/− [29]  C1q−/− or  CD59a−/− (kindly provided by 
B.P. Morgan [20]) mice with Th/Th mice. Knockout ani-
mals were backcrossed against C57BL/6J for more than 12 
generations and housed at a density of 2–5 animals/cage in 
a temperature controlled environment with a 12/12 h light/
dark cycle and food and water ad libitum. If not otherwise 
stated, 6–10 week old mice of both sexes were randomized 
into groups. Adult common marmosets of both sexes (Cal-
lithrix jacchus) were provided by Neu Encepharm (Göttin-
gen, Germany).
EAE induction and scoring
2D2 animals were immunized subcutaneously (s.c.) with 
200 µg  MOG35−55 (purchased from the Institute of Medi-
cal Immunology, University Medical Center Charité, Ber-
lin) emulsified in CFA substituted with 5 mg/ml Mycobac-
terium tuberculosis H37Ra (Difco, 231141). C57BL/6J, 
Th/+ and OSE mice were immunized s.c. with 100 µg 
recombinant rat  MOG1–125/CFA. 300 ng/mouse pertus-
sis toxin (PTX) (List Biological Laboratories, #180) were 
injected i.p. at day 0 and day 2 after immunization. Con-
trol animals were naïve or immunized with CFA only. Age- 
and sex-matched common marmosets were immunized s.c. 
with 50 µg recombinant rat  MOG1–125 emulsified in IFA 
supplemented with 0.25 mg/ml Mycobacterium butyricum 
(Difco, 264010). EAE animals were scored as previously 
described for mice [39] and marmosets [50].
Depletion and blocking experiments
Monocyte depletion in marmoset monkeys was initiated 
14 days after immunization by twice weekly i.v. injections 
of 5 mg/kg DOC-2 Fr-2 (marmoset IgG1-chimeric human-
ized mouse anti-human CCR2 antibody). Controls received 
5 mg/kg marmoset IgG1-chimeric isotype control antibody. 
The administration frequency was reduced to once weekly 
from day 28 to the end of the experiment. In mice, all deple-
tion and blocking experiments started at disease onset. NK 
cells were depleted in Th/+ mice by daily i.p. injections 
of 300 µg of the mouse monoclonal anti-NK1.1 antibody 
(Clone PK136, Bio X Cell, BE0036). Control Th/+ mice 
received 300 µg i.p. of the isotype control antibody C1.18.4 
(Clone C1.18.4, Bio X Cell, BE0085). To block the forma-
tion of the membrane attack complex (MAC) 2 µg of the 
BB5.1 monoclonal antibody against mouse complement 
component C5 (Hycult biotech, HM1073) [23] or a mouse 
IgG1 control antibody (BioLegend, Clone MOPC-21) was 
injected intracerebrally at the time point of stereotactic 
cytokine injection.
Intracerebral stereotactic injections
Mice were anaesthetized i.p. by injection of ketamine/
xylazine and mounted on a stereotactic device (Stoelting 
Co, Germany). The scalp was opened to expose the skull 
and a fine hole was drilled 0.1 mm caudal to the bregma 
and 0.2 mm lateral to the midline. A finely calibrated 
glass capillary was inserted into the brain (0.7 mm depth) 
allowing the intracerebral administration of 2 µl of a mix-
ture composed of 50 ng TNFα (R&D Systems) and 60 ng 
IFNγ (R&D Systems). Immunized animals were injected 
on the 2nd day of disease, animals which received cell-
depleting antibodies on day 3 after EAE onset. Monastral 
blue (Sigma-Aldrich) was added to the cytokine mixture to 
facilitate the identification of the lesions in the tissue.
Adoptive transfer experiments
Spleen cells from 2D2 or OT-II mice were expanded with 
plate bound anti-CD3 (4 µg/ml, Bio X Cell, Clone 145-
2C11, BE0001-1) and soluble anti-CD28 (1 µg/ml, Bio X 
Cell, Clone PV1, BE0015-5) in the presence of 1 ng/ml rm 
IL-12 (R&D systems). Cells were restimulated with 15 µg/
ml  MOG35–55 or 15 µg/ml chicken ovalbumin 323–339 
(OVA) and 30 Gy-irradiated antigen presenting cells for 
3 days and 10 million T cell blasts were injected i.p. into 
 RAG1−/−,  RAG1−/− γc−/− or  RAG2−/− γc−/− animals. 
12 h after adoptive transfer, all animals were s.c. immu-
nized with 10 µg  MOG35–55 or OVA peptide and received 
300 ng PTX i.p. On the 2nd day of EAE 1.5 mg/animal of 
the MOG-specific antibodies 8-18C5 (IgG1 isotype) or Z2 
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(IgG2a isotype) was injected i.v., and animals were sub-
jected to stereotactic surgery.
Motor skill sequence (MOSS) test
Male Th/+ and C57BL/6J mice were individually equipped 
with a running wheel with regularly spaced crossbars 
(conventional wheels) where they could run freely at any 
time for 2 weeks [30]. After this period they were immu-
nized s.c. with a subclinical dose of 10 µg recombinant rat 
 MOG1–125/CFA, therefore, not developing clinical disease. 
The mice were kept on the conventional running wheels 
for further 11 days and then randomized according to their 
wheel running performance into two comparable groups 
which received intracortical stereotactic injections of 2 µl 
PBS or cytokines. One day after surgery, all animals were 
put onto wheels with irregularly spaced crossbars (complex 
wheels). Wheel running performance was recorded contin-
uously by LabVIEW™-based software.
Preparation of CNS mononuclear cells and flow 
cytometry
The meninges were removed and the cortex was separated 
from the white matter 2 days after stereotactic injection, cut 
and digested for 45 min at 37 °C with 2.5 mg/ml Colla-
genase D (Roche) and 1 mg/ml DNAse I (Roche). Mononu-
clear cells were isolated by Percoll gradient centrifugation 
(37%/70%, GE Healthcare) removed from the interphase, 
washed and subsequently blocked with αCD16/32 (BioLe-
gend, Clone 93) for 15 min. The following antibodies were 
used (all from BioLegend or eBioscience): αCD3 (145-
2C11), αCD4 (RM4-5), αCD8 (53-6.7), αCD11b (M1/70), 
αCD11c (N418), αCD19 (eBio1D3), αCD25 (PC61.5), 
αCD45 (30-F11), αFoxP3 (FJK-16S), αNK1.1 (PK-136), 
αNkp46 (29A1.4), αLy6C (HK1.4), αLy6G (1A8), αCCR2 
(R&D 475301), αγδ TCR (eBioGL3), αB220 (RA3-6B2). 
For intracellular αFoxP3 staining, cells were fixed after 
surface staining for 45 min and permeabilized for 30 min 
using the eBioscience FoxP3 staining kit. All flow cytom-
etry data were acquired on a FACS Canto™ II (BD Bio-
science) device and analyzed with the FlowJo software (v. 
7.6.1, Tree Star Inc).
Blood samples of marmoset monkeys were analyzed by 
flow cytometry using the following directly labelled anti-
bodies specific for: CD20 (B-Ly1, DakoCytomation), CD3 
(SP34, BD Bioscience), CD14 (M5E2), CD11b (D12). For 
indirect staining, marmoset or human EDTA blood was first 
stained with the mouse-anti-human CCR2 antibody DOC-2 
(5 µg/ml) followed by PE-labelled rabbit anti-mouse F(ab)2 
(DakoCytomation), or with the humanized or marmoset 
chimeric DOC-2 Fr-2 followed by FITC-labelled goat anti 
human Fcγ specific F(ab’)2 (Jackson Immunoresearch).
Blood–brain barrier permeability
Th/+ mice, healthy or previously immunized with 
 rMOG1–125, were stereotactically injected with IFNγ and 
TNFα as described above and perfused 24 h afterwards. 
One hour before perfusion, the mice received i.v. injections 
of 100 µg FITC-albumin/g body weight (albumin–fluores-
cein isothiocyanate conjugate, Sigma, A9771).
Histology and immunohistochemistry
Mice Mice were perfused transcardially at different 
time points: 24 h, day 5, day 10, day 20 and day 40 after 
cytokine injection with cold PBS followed by 4% para-
formaldehyde (PFA). Brains and spinal cords were post-
fixed for 2 days and then kept in PBS until dissected. Spi-
nal cord and brain sections containing the injection site, 
identified by the trace of Monastral blue, were paraffin-
embedded. Sections between 3 µm were cut and processed 
for immunohistochemistry (IHC) according to standard 
protocols. Cortical demyelination was evaluated on sec-
tions stained with a rabbit anti-myelin basic protein (MBP) 
antibody (Dako, A0623, 1:1000) using a Tyramide Signal 
Amplification kit (TSA™ Kit 21, Invitrogen). To charac-
terize inflammatory infiltrates we stained with antibodies 
for T cells (rabbit anti-CD3, DCS, C1597C01, 1:100) and 
for microglia/macrophages (rat anti-Mac-3, BD Pharmin-
gen™, Clone M3/84, 553322, 1:200).
To identify mature oligodendrocytes and oligodendro-
cyte precursor cells (OPC) in the cortical demyelinated 
areas, double-IHC was performed using a rabbit anti-TPPP/
p25 antibody against tubulin polymerization-promoting 
protein (Abcam, 92305, 1:500) or a rabbit anti-Olig2 anti-
body (IBL, 18953, 1:300) respectively, on sections previ-
ously stained with rat anti-MOG antibody (purified in our 
laboratory). Double-IHC was also performed for myelin 
(anti-MOG) and amyloid precursor protein (APP, Chemi-
con, MAB348, 1:2000) as a marker of axonal damage or 
NeuN (Millipore, MAB377, 1:200) for neurons. Polymor-
phonuclear cells were detected by enzyme histochemistry 
using a chloroacetate esterase assay (Naphtol AS-D Chlo-
roacetate esterase kit; Sigma-Aldrich).
NK cells infiltrating the cortex of stereotactically 
injected Th/+ mice were detected in cryosections using the 
primary goat anti-mouse antibody NKp46/NCR1 (R&D 
Systems, AF2225, 1:50). Briefly, mice where perfused 
with cold PBS. The brain was sectioned, mounted in OCT 
medium (Tissue-Tek; Sakura Finetek USA) and frozen in 
isopentane (Sigma-Aldrich) pre-cooled in liquid nitro-
gen. Serial sections 6 μm thick were cut in a cryostat at 
−20 °C and fixed in ethanol for 1 h before applying the 
NKp46 antibody. Antibody binding was visualized using 
DAB. To distinguish NK from NKT cells, we performed 
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double-immunofluorescence on cryosections from stereo-
tactically injected Th/+ mice using the goat anti-NKp46 
antibody described above and a rabbit anti-CD3 antibody 
(Dako, A0452, 1:50). For visualizing NKp46, a donkey 
anti-goat biotinylated secondary antibody (GE Healthcare 
Ltd, RPN1025, 1:200) was added for 1 h at room tempera-
ture in 10% FCS/PBS, followed by 30 min incubation with 
Cy™3-conjugated streptavidin (Jackson ImmunoResearch 
Lab, 016160184, 1:100). The  AlexaFluor® 488 goat anti-
rabbit antibody (Life Technologies, A11034, 1:200) was 
used to visualize the CD3 signal. Nuclei were counter-
stained with 4′,6-diamino-2-phenylindole (DAPI). Sections 
were examined using a fluorescence microscope (Olympus 
BX51, Germany).
Spinal cord sections from Th/+  CCR2+/+ and Th/+ 
 CCR2−/− were stained with Luxol fast blue (LFB)/peri-
odic acid-Schiff (PAS) and evaluated for the extent of 
demyelination. Finally, paraffin-embedded brain sections 
from Th/+ mice injected with FITC-albumin were immu-
nolabelled with a rabbit anti-FITC antibody conjugated to 
horseradish peroxidase (Dako, P5100, 1:50) to measure the 
area of FITC extravasation.
Marmoset monkeys Before transcardial perfusion with 
PBS and ice-cold 4% PFA, the animals received a lethal 
dose of ketamine/pentobarbital. Heads and spinal cords 
were post-fixed in 4% PFA, dissected and embedded in par-
affin after 24 h. For the assessment of cortical demyelina-
tion and the identification of T cells in brain sections, we 
used the same primary antibodies as for mice (anti-MBP, 
enhanced with tyramide, and anti-CD3). For the detection 
of macrophages/monocytes the antibody MAC387 (mouse 
anti-L1 antibody MAC387, GeneTex, GTX6577, 1:150) 
was used. Spinal cord sections were in addition stained 
with LFB/PAS.
Morphometric analysis
The quantification of cortical demyelination was performed 
on MBP-immunostained sections in mouse brains at the 
aforementioned time points. Images were acquired using a 
40× magnification of a light microscope (Olympus BX51, 
Germany) equipped with a digital camera (Software CellS-
ens Dimension v.1.7.1, DP71, Olympus, Germany). To 
measure cortical demyelination in the marmosets, MBP-
immunolabelled sections were scanned using the Key-
ence Bio REVO BZ-X710 microscope (Keyence, Japan). 
Compound images of the entire coronal brain section ana-
lyzed were generated by combining single images using 
the BZ-II analyzer software (Keyence, Japan). ImageJ (v. 
1.46r, NIH, USA) was used to measure the subpial demy-
elinated area and the extent of perivascular cortical demy-
elination in the digital composite images. In mice, subpial 
demyelination was quantified in the ipsilateral (injected) 
brain hemisphere, whereas perivascular demyelination was 
measured in both the ipsi- and contralateral cortex. Subpial 
demyelination (%) and the area of perivascular demyelina-
tion  (mm2) are reported. Subpial demyelination was calcu-
lated as follows:
Since cortical demyelination in mice was most exten-
sive at day 5 post stereotactic injection, we selected this 
time point (if not stated otherwise) for quantitative analy-
sis. Cell densities were determined using a 10 × 10 ocu-
lar morphometric grid (at 400× magnification) (Olympus, 
Japan), and the results were expressed as cells/mm2. The 
densities of p25+, Olig2+ and NeuN+ cells were assessed 
in the ipsilateral cortical layers I and II/III of C57BL6/J 
mice and in the subpial demyelinated areas across the 
same layers in Th/+ mice. The analysis of  APP+ axons 
was restricted to the perivascular demyelinated areas in 
both hemispheres. For assessment of blood–brain bar-
rier permeability the area of FITC-albumin extravasation 
was measured using ImageJ. To this end, a color decon-
volution plugin for ImageJ was used [45], and the thresh-
old established for quantifying the intensity of the brown 
(DAB) channel was set at (0; 150). For the analysis of mac-
rophages/activated microglia in mice, the number of intra-
cortical Mac-3+-perivascular cuffings was counted in both 
hemispheres. For the purpose of quantification, infiltrates 
restricted to the Virchow–Robin space, without evidence 
for cellular transmigration into the cortical parenchyma, 
were not considered bona fide perivascular infiltrates. The 
area of spinal cord demyelination in mice (Th/+  CCR2+/+, 
Th/+  CCR2−/−) and marmosets was measured on LFB/
PAS stained sections using ImageJ. Digital images were 
acquired from at least eight transversal spinal cord sections 
from each animal, the demyelinated areas were measured 
and reported as % of total white matter. The densities of 
KiM1P+ macrophages/activated microglia and T cells 
in biopsies from early MS cases were determined using 
an ocular morphometric grid (Olympus, Japan). Immu-
nostained cells were counted in regions with subpial corti-
cal demyelination, as well as in normal appearing cortical 
regions (NAGM). At least five separate visual fields were 
quantified for each cortical region within each sample. 
Densities were reported as cells/mm2. The investigators 
(NLD, CS) were blinded to the experimental groups.
qRT‑PCR
Th/+  CCR2+/+ or Th/+  CCR2−/− mice were perfused with 
PBS 2 days after stereotactic cytokine injection. Brains 
were dissected and the ipsilateral cortex near the injection 
site was separated from the white matter and conserved in 
Subpial demyelination (%) =
(subpial demyelinated area)




QIAzol Lysis Reagent (Qiagen). RNA was isolated from the 
tissue using the RNeasy Micro Kit (Qiagen, Germany) and 
subsequently transcribed into cDNA using the High Capac-
ity RNA-to-cDNA™ Kit (Life Technologies). From the 
cDNA, 12.5 ng were used per PCR reaction. Quantitative 
PCR was performed on the iQ5™ Real Time PCR Detec-
tion System (BIO-Rad) using the qPCR Core Kit obtained 
from Eurogentec. The following FAM labeled primers/
probes  (TaqMan® Gene Expression Assays) were selected 
to be intron spanning from Life Technologies: Gapdh 
(Mm99999915 g1), TNF-α (Mm00443258_m1), NOS2/
iNOS (Mm00440502_m1) and CCL2 (Mm00441242_m1). 
The expression levels of TNF-α, NOS2/iNOS and CCL2 
are indicated as the percentage of the housekeeping gene 
Gapdh.
Statistics
Normality tests (D’Agostino and Pearson omnibus normal-
ity test) were applied to all data sets. If the samples fol-
lowed a normal distribution, the unpaired t test or a paired 
t test were applied. In the absence of normality, the non-
parametric Mann–Whitney U test or the Wilcoxon signed-
rank test were used. One-way-ANOVA followed by Dunn’s 
Multiple Comparison post hoc test was used for compari-
sons between three or more groups. p < 0.05 was consid-
ered to be significant. Unless otherwise specified, all results 
are shown as mean ± SD.
Role of the funding source
The sponsors of this study had no role in study design, data 
collection, data analysis, data interpretation and writing of 
the manuscript. The corresponding authors had full access 
to all the data in the study and had final responsibility for 
the decision to submit the manuscript.
Results
In our cohort of 740 biopsied patients with inflamma-
tory white matter demyelination compatible with MS, 26 
patients harbored subpial cortical demyelinated lesions, 
which extended from the subpial area to layers V–VI, 
reflecting 19% of the patients where cortex was available 
for microscopic analysis (Supplemental Fig. 1).
We found 7/26 cortical demyelinated lesions with evi-
dence for ongoing demyelination as indicated by the pres-
ence of MBP-laden phagocytes in all clinical MS subtypes 
(2 CIS, 4 RRMS, 1 SPMS). Foamy  KiM1P+ macrophages/
activated microglia were conspicuous in those cases (active 
and demyelinating according to Kuhlmann et al., Fig. 1l). 
The remaining 19 cortical demyelinated lesions were 
staged active and post-demyelinating [27]. The numbers 
of KiM1P+ macrophages/activated microglia observed in 
cortical demyelinated lesions significantly exceeded those 
found in the non-demyelinated, normal appearing cortex in 
both upper (L1/2) and lower (L3) cortical layers (Fig. 1d, 
i, n). Within the demyelinated cortex, densities of  KiM1P+ 
cells were significantly higher in the immediate subpial cor-
tical layer 1/2 as opposed to layer 3 (Fig. 1p). Macrophages 
in MS can be derived from either microglia cells or invad-
ing monocytes, and in white matter demyelination, mono-
cyte-derived macrophages most likely predominate. We, 
therefore, performed CD14/CCR2 immunofluorescent dou-
ble-labelling studies in eight cases (four with active corti-
cal demyelination), in which tissue was available, to deter-
mine monocyte recruitment into the demyelinated cortex 
(Fig. 1y). Three main populations could be distinguished: 
 CD14−  CCR2+ cells often with rounded, amoeboid mor-
phology were found perivascularly, as well as scattered in 
the cortical parenchyma.  CD14−  CCR2+ cells were Iba-
1+, but most of the  CCR2+ cells (>95%) were negative for 
the microglia specific markers TMEM119 and  P2Y12 and 
the pan T cell marker CD3. A proportion of  CCR2+ cells 
showed foam cell morphology and co-expressed KiM1P. 
 CD14+  CCR2+ cells were more restricted and mainly 
identified perivascularly in 4/8 cases, and a predominantly 
perivascular distribution was also observed for  CD14+ 
 CCR2− cells. Numbers of  CCR2+ cells were low in the 
normal appearing cortex and increased in demyelinated 
areas (Fig. 1v–z, Supplemental Fig. 2).
Infiltration with  CD3+ T cells was significantly higher 
in demyelinated compared to normal-appearing cortical 
gray matter in both cortical layers 1/2 and 3 (Fig. 1e, j, o), 
and within the demyelinated cortex,  CD3+ T cell numbers 
were higher in cortical layer L1/2 than in cortical layer 
L3 (Fig. 1q). In our cohort, few patients with substantial 
perivascular lymphocyte infiltration could be identified 
(Fig. 1s). CD4 and CD8 T cell subsets were present in sim-
ilar frequencies (Supplemental Fig. 3). Few  GrB+  CD3− 
NK cells were predominantly detected perivascularly and 
rarely in the cortical parenchyma, but not in the non-demy-
elinated cortex (Fig. 1t, u).
Leptomeninges overlying subpial cortical demyelina-
tion were present in 13 of our 26 patients and displayed 
higher numbers of macrophages (Fig. 2g, h), T cells 
(Fig. 2a, b) and B cells (Fig. 2c, d) compared to those 
localized adjacent to non-demyelinated cortical tissue 
(Fig. 2). Also,  CCR2+ monocytes were found, mainly 
perivascularly, in the leptomeninges overlying demyeli-
nated cortex (Fig. 2i). However, tissue of only one patient 
comprising leptomeninges overlying normal-appear-
ing cortex was available for CCR2 IHC for compari-
son (Fig. 2j). Leptomeningeal plasma cells were found 
adjacent to demyelinated and non-demyelinated cortex 
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Fig. 1  Increased adaptive and innate immune cell infiltration in demy-
elinated as compared to normal appearing cortical gray matter. In com-
parison with regularly myelinated normal appearing cortical gray matter 
(a–c), demyelinated cortex obtained at biopsy (f–h) shows higher densi-
ties of KiM1P+ macrophages/activated microglia (d, g, i, n) and T cells 
(e, h, j, o). An example of a cortical lesion with ongoing demyelination 
as evidenced by MBP-laden phagocytes (arrows, k–m). In addition to 
foamy macrophages (k, l), T cells are found perivascularly, as well as in 
the parenchyma (m). A gradient of macrophage/microglia (p) and T cell 
densities (q) is apparent with higher densities in the superficial cortical 
layers 1/2 compared to layer 3. Multilayered perivascular T cell cuffs in 
the cortex, identified by the presence of  APP+ neurons, were only seen 
in rare cases (r, s). The patient shown here presented with neuropsychi-
atric symptoms (patient no. 25).  GrB+/CD3− natural killer (NK) cells 
were observed perivascularly and only in demyelinated, but not nor-
mal appearing cortex (t, u, arrow).  CCR2+ monocytes were mainly 
observed perivascularly, with some cells scattered in the parenchyma (v, 
w, x). CCR2/CD14 double-positive cells were observed perivascularly 
in patients with ongoing demyelination, indicating active myeloid cell 
recruitment into the cortex (y, arrows). Fluorescent double-immunohis-
tochemistry of CCR2 and the pan-macrophage marker KiM1P identi-
fies CCR2/KiM1P double-positive cells (z). All data are presented as 
mean ± SD. d, e One-way ANOVA followed by Dunn’s Multiple Com-
parison post hoc test; i, j, n paired t test; o Wilcoxon signed-rank test; p, 
q paired t test and Wilcoxon matched pairs signed-rank test. All immu-
nohistochemistries were performed with diaminobenzidine (DAB; brown 
color), except for CD3 (Fast Blue, in double labelling with GrB). Cell 
nuclei are counterstained with hematoxylin. APP amyloid precursor pro-
tein, NAGM normal appearing cortical gray matter, CDM cortical demy-
elination, GrB granzyme B, L1/2 cortical layer 1 and 2, L3 cortical layer 3
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(Fig. 2e, f), and NK cells were exceedingly rare (Fig. 2k). 
In a highly inflammatory cortically demyelinated MS 
patient  CD14+  CCR2+ and  CD14+  CCR2− monocytes 
were found to directly infiltrate the subpial brain paren-
chyma (Fig. 2l).
In summary, our study in a cohort of early and in part 
actively demyelinating cortical lesions demonstrates both 
adaptive and innate inflammatory cells in the cortex as well 
as the overlying meninges and presents evidence for early 
invasion of  CD14+  CCR2+ and  CD14+  CCR2− monocytes. 
Furthermore, a gradient of inflammatory cell infiltration 
was observed, with higher densities in the subpial cortex.
Cortical demyelination requires a conformation‑specific 
antibody response against myelin
In a next step, we strived to model cortical demyelination in 
the mouse to obtain an easily manipulable system in which 
the relative contribution of adaptive and innate immune cells 
as well as humoral components for cortical demyelination 
Fig. 2  The intensity of meningeal inflammation associates with cor-
tical demyelination. Meningeal inflammation, mostly arranged in a 
perivascular fashion, was found adjacent to demyelinated and non-
demyelinated cortical areas. T lymphocyte (a, b) and macrophage 
(g, h) infiltration was significantly higher in areas overlying demyeli-
nated cortex. Also, macrophages and T cells were more abundant than 
B cells (c, d) and plasma cells (e, f). NK cells were exceedingly rare 
(k).  CCR2+ monocytes were found perivascularly in the leptomenin-
ges overlying both demyelinated and normal-appearing cortical gray 
matter (i, j). Meningeal  CD14+  CCR2+ and  CD14+  CCR2− mono-
cytes overlying an actively demyelinating cortical lesion in a patient 
with monocyte invasion into the subpial cortex (l). Data are presented 
as mean ± SD; Mann–Whitney test
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can be assessed. Cortical demyelination is not a regular fea-
ture of experimental autoimmune encephalomyelitis (EAE) 
in  MOG35–55-peptide- or  rMOG1–125-immunized C57BL/6 
mice. To mimic the pro-inflammatory cytokine milieu found 
in the CSF of patients with cortical demyelination, we ste-
reotactically injected TNFα and IFNγ into the right motor 
cortex of  MOG35–55-peptide immunized 2D2 mice (TCR 
transgenic for MOG),  rMOG1–125-immunized C57BL/6 
mice or  rMOG1–125-immunized Th/+ mice (BCR trans-
genic for MOG) at the 2nd day of clinical EAE. Subpial 
and perivascular cortical demyelination were only observed 
in Th/+ mice (Fig. 3a), which carry the Ig heavy chain 
knockin of 8-18C5, an established demyelinating MOG-
specific antibody. Of note, Th/+ mice developed corti-
cal demyelination subpially and intracortically in both the 
injected and non-injected hemispheres (Fig. 3a–c). Demy-
elination in the cortex was most pronounced on day 5 after 
injection and paralleled by a significant reduction in  p25+ 
mature oligodendrocytes (Fig. 3d, h, l). In line with previ-
ous studies demonstrating axonal damage in cortical MS 
lesions, the density of damaged  APP+ axons was signifi-
cantly increased in perivascular cortical demyelination of 
Th/+ mice compared to corresponding cortical regions in 
C57BL/6J mice (Fig. 3f, j, n), while the density of neurons 
in the demyelinated cortex was not reduced (Fig. 3g, k, o). A 
significant decline in perivascular macrophage cuffings and 
T cell densities could be observed on days 20 and 40 after 
lesion induction (Fig. 3s, t), and lesions were significantly 
remyelinated on day 20 perivascularly and on day 40 subpi-
ally (Fig. 3p–r). Concordant with the maximum of demy-
elination observed, cortically demyelinated Th/+ mice were 
impaired in the motor skill sequence (MOSS) test between 
days 4 and 6 after lesion induction (Supplemental Fig. 4).
The classical pathway of complement activation is 
dispensible for cortical demyelination in Th/+ mice
MOG-specific antibodies targeting conformational epitopes 
are a prerequisite for cortical demyelination in our animal 
model. They might bind to their cognate antigen on the cell 
surface of oligodendrocytes and activate C1q, the first com-
ponent of the classical complement pathway that leads to 
target cell killing by complement-dependent cytotoxicity 
(CDC) via membrane attack complexes. In addition, elimi-
nation of antibody-opsonized cells might be mediated by 
NK cells, macrophages, monocytes and neutrophils, which 
are activated via specific IgG receptors sensing surface 
bound IgG antibodies. To assess the relative importance of 
humoral and cellular effector mechanisms for the patho-
genesis of myelin damage in subpial and perivascular corti-
cal demyelination, we first strived to detect the membrane 
attack complex in cortical demyelinated lesions in human 
MS biopsies. Although we detected subpial IgG leakage in 
patients with ongoing cortical demyelination (Supplemen-
tal Fig. 5 a, c), no evidence of terminal complement acti-
vation was found (not depicted). Next, we prevented the 
generation of the membrane attack complex (MAC) in our 
animal model by a specific antibody directed against C5 
(BB5.1, the mouse analogue of eculizumab) thereby inhib-
iting its cleavage [51]. Inhibiting terminal complement acti-
vation reduced subpial cortical demyelination, whereas the 
extent of perivascular cortical demyelination was not modu-
lated (Fig. 4a, b). If we compared cortical demyelination in 
C1q-deficient mice and controls with EAE which received 
the potent complement-activating and MOG-specific anti-
body Z2 i.v. prior to stereotactic cytokine injections, the 
extent of cortical demyelination in C1q-deficient animals 
was equivalent to controls (Fig. 4c, d). To gain further 
insight whether CDC is relevant for cortical demyelina-
tion in Th/+ mice, we established Th/+  C1q−/− and Th/+ 
 CD59a−/− mice, the latter being deficient for a major mem-
brane inhibitor of terminal complement activation in oligo-
dendrocytes. Th/+  C1q−/− and Th/+  C1q+/+ mice did nei-
ther differ in MOG-specific antibody titres (not depicted) 
nor in the extent of cortical demyelination (Fig. 4e, f). Fur-
thermore, the extent of cortical demyelination was similar 
in Th/+  CD59a−/− and Th/+  CD59a+/+ mice (Fig. 4g, h). 
In summary, we provide evidence that CDC activated via 
the classical complement pathway unlikely contributes to 
cortical demyelination in Th/+ mice.
We further characterized the cortical inflammatory infil-
trate by flow cytometry and identified both adaptive (T and 
B cells) and innate immune cells (monocytes, granulocytes 
(PMN) and natural killer (NK) cells) in the demyelinated 
cortex of Th/+ mice on day 3 after lesion induction (Fig. 4i). 
To gain insight into the relevance of individual immune 
cell populations for cortical demyelination, we selectively 
depleted individual immune cells by specific antibodies 
or used transgenic mice genetically deficient for adaptive 
immune cells, NK cells or inflammatory monocytes.
Natural killer cells contribute to perivascular cortical 
demyelination
NK cells are the classical effectors of antibody-dependent 
cellular cytotoxicity (ADCC) against IgG-coated targets 
and were detected around vessels in both demyelinated 
cortical lesions of MS biopsies (Fig. 1t) and in cortically 
demyelinated Th/+ mice (Fig. 5g, h). When we effi-
ciently depleted NK cells in the blood and cortex of Th/+ 
mice prior to stereotactic surgery (Fig. 5a–c), the extent 
of subpial cortical demyelination was unaffected by NK 
cell depletion, but perivascular cortical demyelination 
was significantly diminished (Fig. 5d–f). Of note, NK 
cell depletion did not affect the numbers of perivascular 
or meningeal  CD3+ T cells (Fig. 5k, l). To further support 
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Fig. 3  Cortical demyelination in Th/+ mice with demyelinating 
antibodies. a Subpial and perivascular cortical demyelination as 
assessed by immunohistochemistry (IHC) for MBP (brown color) 
on day 5 after stereotactic cytokine injection in Th/+ mice (top) and 
C57BL/6J mice (bottom). b, c Subpial cortical demyelination was 
quantified on MBP-immunostained brain sections as percentage of 
total cortical area of the injected hemisphere. The extent of perivas-
cular cortical demyelination is given in  mm2 (C57BL/6: n = 5; Th/+: 
n = 13). Data are from three independent experiments and presented 
as mean ± SD; Mann–Whitney test. Representative IHC of mature 
oligodendrocytes (d, h), oligodendroglial cells including OPC (e, i), 
axons (f, j) and neurons (g, k) in cortical demyelinated areas of Th/+ 
(top) and corresponding non-demyelinated cortex in C57BL/6J mice 
(bottom). Cell markers are depicted in blue (Fast Blue), myelin oligo-
dendrocyte glycoprotein (MOG) in brown (DAB). Exemplary  APP+ 
axons as well as  p25+ and  Olig2+ cells are indicated by arrowheads 
and shown in greater detail (insets). Dotted lines in the images mark 
the border between demyelinated and non-demyelinated cortical 
areas. Scale bars: insets 20 µm. Densities of  p25+ oligodendrocytes 
(l),  Olig2+ cells (m),  APP+ damaged axons (n) and  NeuN+ neu-
rons (o) were determined in subpial cortical demyelination in Th/+ 
mice and corresponding cortical layers in C57BL/6J mice. A total 
of 7 Th/+ and 5 C57BL/6J mice were analyzed in two independent 
experiments and are presented as mean ± SD; Mann–Whitney test. 
p–t Resolution of inflammation and lesion repair of cortical demy-
elination in Th/+ mice. The extent of subpial and perivascular corti-
cal demyelinated lesions was assessed by MBP IHC on days 5, 10, 
20 and 40 post cytokine injection (p). Asterisks mark parenchymal 
vessels. (q, r) Quantitative analysis of subpial cortical demyelina-
tion and perivascular cortical demyelination (d5: n = 13, three inde-
pendent experiments; days 10, 20, 40: n = 6 each, two independent 
experiments). Data are presented as mean ± SD; one-way ANOVA 
followed by Dunn’s Multiple Comparison post hoc analysis. Quan-
tification of Mac-3 (macrophages, s) and CD3 (T cells, t) IHC on 
days 5, 10, 20 and 40 post stereotactic cortical cytokine injections. 
Representative data of two independent experiments for each time 
point presented as mean ± SD. Mac-3 (n = 6, for each day), T cells 
(n = 6, d5 and d20; n = 5, d10 and d40); one-way ANOVA followed 
by Dunn’s Multiple Comparison post hoc analysis
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the relevance of NK cells to perivascular cortical demy-
elination, we adoptively transferred activated MOG-spe-
cific 2D2 T cells into  RAG1−/− (no mature T and B cells) 
and  RAG1−/− γc−/− (no mature T and B cells, no NK 
cells) mice. At disease onset, all animals received 1.5 mg 
of the demyelinating MOG-specific IgG2a antibody Z2 
i.v. and underwent stereotactic cytokine injections into 
the motor cortex. Whereas  RAG1−/− and  RAG1−/− γc−/− 
mice developed similar subpial cortical demyelination, 
perivascular cortical demyelination was significantly 
higher in  RAG1−/− compared to  RAG1−/− γc−/− animals 
(Fig. 5i, j). Our experiments thus demonstrate that NK 
cells are relevant for perivascular cortical demyelination 
in the presence of a pathogenic antibody response, which 
is in line with their predominant perivascular localization 
in the inflamed cortex.
Encephalitogenic T cells are dispensable for subpial 
type 3, but not perivascular type 2 cortical 
demyelination
Clinical trials in MS have been interpreted in a way that 
the progressive disease phase might be less dependent 
on peripherally recruited adaptive immune cells. Since 
Fig. 4  The classical complement pathway does not substantially con-
tribute to cortical demyelination. a, b Quantitative assessment of sub-
pial and perivascular cortical demyelination in MBP-immunostained 
brain sections of cytokine injected Th/+ mice, which received the C5 
convertase blocking antibody BB5.1 or an isotype control antibody 
(n = 9 animals/group, analyzed in two independent experiments; 
unpaired t test). c, d Quantitative assessment of subpial and perivas-
cular cortical demyelination in MBP-immunostained brain sections 
of  C1q−/− or C57BL/6 (C1q+/+) mice, which received 1.5 mg of the 
MOG-specific, complement-fixing antibody Z2 i.v. prior to stereo-
tactic cytokine injections. e, f Quantitative assessment of subpial and 
perivascular cortical demyelination in MBP-immunostained brain 
sections of Th/+  C1q−/− (n = 6) and Th/+  C1q+/+ (n = 9) mice; 
representative data of two independent experiments. g, h Quantita-
tive assessment of subpial and perivascular cortical demyelination 
in MBP-immunostained brain sections of Th/+  CD59a−/− and Th/+ 
 CD59a+/+ mice; n = 9/group, representative data of two independ-
ent experiments. i Leukocyte subsets in cortical demyelination. Leu-
kocytes isolated from the demyelinated cortex of Th/+ mice (n = 3) 
were analyzed by multicolor flow cytometry on day 2 post injection. 
All data are presented as mean ± SD
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Fig. 5  NK cells contribute to perivascular cortical demyelination. a–c 
Analysis of NK depletion efficiency in the blood (before stereotactic 
injection) and in the cortex (d5 after stereotactic injection) of Th/+ 
mice by multicolor flow cytometry. b, c Quantification of NK cells in 
the blood (b) and the cortex (c) of NK cell depleted (PK136 antibody, 
n = 4) and control mice (C1.18.4 antibody, n = 3). Data are given as 
mean ± SD and were analyzed in two independent experiments; 
Mann–Whitney test. d Subpial and perivascular cortical demyelination 
as assessed by IHC for MBP (brown color) on day 5 after stereotactic 
cytokine injection in NK cell depleted Th/+ mice (PK136 antibody, 
bottom) and controls (C.1.18.4 antibody, top). Red squares in the brain 
overviews mark the magnified areas in the subpial ipsilateral photo-
graphs. Dotted lines define the respective subpial demyelinated areas. 
Vessel lumina are marked by asterisks. e, f Quantitative analysis of sub-
pial and perivascular cortical demyelination in MBP-immunostained 
brain sections of 7 animals per group. Data are presented as mean ± SD 
and were analyzed in two independent experiments; unpaired t test with 
Welch correction. g Representative IHC of perivascularly located NK 
cells (NKp46, arrowheads) in the cortex of Th/+ mice. Asterisks mark 
the vessel lumen. h Immunohistochemical double-labelling of NKp46 
(red) and CD3 (green). A perivascular NK cell is marked with a white 
arrowhead. Nuclei were counterstained with DAPI (blue signal). i, j 
Quantitative analysis of subpial and perivascular cortical demyelina-
tion in 2D2 T cell and anti-MOG antibody (Z2) transferred  RAG1−/− 
(n = 5) and  RAG1−/− γc−/− mice (n = 4). k, l Quantitative analysis 
of meningeal and perivascular  CD3+ T cells in NK cell depleted Th/+ 
mice and controls. Data are presented as mean ± SD analyzed in three 
independent experiments; Mann–Whitney test
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cortical demyelination is prominent in chronic MS, we 
scrutinized whether T cells are central to cortical lesion 
formation in our model. Also, we wanted to clarify, 
whether CNS-antigen specificity and T cell activation 
influence cortical demyelination. To this end, we com-
bined T- and B cell receptor transgenic mice for MOG 
(OSE:  TCRMOG × IgGMOG) and transferred activated 
MOG-specific T cells  (TCRMOG, named 2D2) or acti-
vated, ovalbumin-specific T cells (OT-II, which recog-
nize an antigen not present in mice) into mice deficient 
for adaptive immune cells  (RAG1−/− mice). Surpris-
ingly, we found that T and B cells were not immediately 
required for subpial cortical demyelination in the pres-
ence of demyelinating antibodies and stereotactically 
applied cytokines (Fig. 6a, b). However, activated CNS-
antigen specific T cells were a prerequisite for perivascu-
lar cortical demyelination (Fig. 6c–f). These results were 
supported by experiments assessing the permeability of 
the cortical blood–brain barrier via the extravasation of 
FITC-albumin in healthy, non-immunized Th/+ mice ver-
sus diseased Th/+ mice harboring CNS-antigen specific, 
activated T cells (Fig. 6g). Perivascular cortical extrava-
sation of FITC-albumin was significantly more pro-
nounced in diseased than in healthy Th/+ mice, whereas 
subpial extravasation of serum proteins was substantial 
in both experimental paradigms 24 h after lesion induc-
tion (Fig. 6h, i). This indicates that intracortically applied 
cytokines are sufficient to increase the permeability of 
meningeal and subpial vessels readily while intracorti-
cal vessels require the combined action of cytokines and 
encephalitogenic T cells to become permeable to serum 
proteins, such as albumin and IgG. In line, IgG leakage 
was detected subpially in a single patient with ongoing, 
active cortical demyelination (Supplemental Fig. 5).
CCR2+ monocytes are required for inflammatory 
cortical demyelination
Quantitatively, macrophages are by far the dominant inflam-
matory cell population in MS and correlate with active demy-
elination. Recent evidence has been provided that blood-
derived  CCR2rfp/+ monocytes give rise to highly phagocytic 
and inflammatory macrophages, which initiate demyeli-
nation in EAE [53]. To assess the contribution of  CCR2+ 
monocytes for cortical demyelination, Th/+  CCR2−/− 
mice and Th/+  CCR2+/+ controls were immunized with 
 rMOG1–125 and received stereotactic injections on day 2 
after EAE onset. In line with previous reports in CCR2-defi-
cient animals [17], Th/+  CCR2−/− mice developed EAE at 
a comparable severity, albeit at later time points than Th/+ 
 CCR2+/+ controls (Table S2). The recruitment of inflamma-
tory monocytes into the cortex was significantly impaired in 
Th/+  CCR2−/− mice compared to Th/+  CCR2+/+ controls 
on day 2 after stereotactic injection (Fig. 7a, b). Consistent 
with the flow cytometry data, Th/+  CCR2−/− mice had sig-
nificantly less intracortical Mac-3+ perivascular cuffings in 
both hemispheres than Th/+  CCR2+/+ mice (Fig. 7c, d) and 
reduced mRNA levels of monocyte-related genes such as 
TNFα and iNOS (Fig. 7e–g). Most importantly, both subpial 
cortical demyelination and perivascular cortical demyelina-
tion were significantly reduced in Th/+  CCR2−/− compared 
to Th/+  CCR2+/+ mice (Fig. 7h, i).
Depletion of  CCR2+ monocytes reduces cortical 
demyelination in marmosets with EAE
The detection of  CD14+  CCR2+ double-positive monocytes 
invading the cortex with ongoing, active demyelination 
(Figs. 1y, 2l) let us hypothesize that targeting CCR2 might 
represent a valid treatment strategy against cortical demyeli-
nation. We, therefore, developed a novel monoclonal mouse 
anti-human CCR2 antibody (DOC-2) cross-reacting with 
marmoset CCR2 (Fig. 7j–l). After humanization, DOC-2 
antibodies (now named DOC-2 Fr) retained their capability 
to bind to human and marmoset monocytes (Fig. 7k, l), were 
well tolerated, and efficiently depleted monocytes in healthy 
marmosets at a dose of 5 mg/kg given weekly i.v. (Fig. 7m). 
Next, we specifically depleted  CCR2+ monocytes (but not 
T and B cells) in marmosets with EAE using twice weekly 
i.v. injections of DOC-2 Fr-2 starting 2 weeks after immu-
nization (Fig. 8a–e). Monocyte-depleted animals displayed 
less subpial type 3 cortical demyelination and significantly 
less perivascular type 2 cortical demyelination compared 
to isotype-treated controls (Fig. 8f–h), in line with an ame-
liorated clinical disease course (Fig. 8i). In summary, these 
observations provide evidence that inflammatory monocytes 
are crucial for the initiation of cortical demyelination and 
thus represent a specific and rational therapeutic target for 
the reduction of inflammatory cortical pathology.
Discussion
The cerebral cortex is a major site of disease-related pathol-
ogy in MS, whereby subpial cortical regions are the most 
frequently and intensely affected. We demonstrate here in 
biopsy tissue of MS patients that subpial lesion areas are 
more densely infiltrated by T cells and macrophages than 
deeper cortical lesion areas, supporting the idea that acti-
vated immune cell invasion primarily takes place via pial 
vessels. In addition, ongoing recruitment of  CCR2+ mono-
cytes accompanying active demyelination was observed, 
even in a patient with long-standing, progressive MS. 
Assessing the relevance of cellular and humoral immune 
mediators for cortical demyelination in an anti-myelin 
antibody-dependent experimental model, we show here 
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that the requirements for immunological effector func-
tions differ between subpial type 3 and perivascular type 
2 cortical lesions (summarized in Fig. 9). Whereas cortical 
demyelination in both cortical lesion types was depend-
ent on the presence of pathogenic demyelinating antibod-
ies and inflammatory monocytes, the cellular requirements 
for perivascular cortical demyelination were more critical 
and included activated encephalitogenic T cells. Also, NK 
cells strongly aggravated the extent of perivascular cortical 
demyelination.
The less restrictive requirements for subpial corti-
cal demyelination were corroborated by the observation 
that the intracortical injection of cytokines into healthy 
Th/+ mice readily increased the permeability of subpial 
but not of intracortical vessels to FITC-albumin. This is 
in line with the well-established increased permeabil-
ity of human leptomeningeal endothelial cells compared 
to brain parenchymal endothelial cells and the reported 
stronger reactivity of meningeal blood vessels to pro-
inflammatory cytokines [40]. Accordingly, the IgG leak-
age detected in an individual MS patient with active cor-
tical demyelination was located subpially. Thus, distinct 
barrier properties within the cortical vasculature might 
facilitate the observed preferential subpial lesion localiza-
tion in MS patients.
Interestingly, terminal complement activation is not 
the relevant antibody effector function for cortical demy-
elination in our animal model and its relevance for MS in 
general and for cortical demyelination in particular is dis-
cussed controversially. While Watkins and colleagues found 
increased numbers of cells, in particular neurons, in corti-
cal gray matter lesions, which immunostained for the mem-
brane attack complex (MAC) [52], Brink and colleagues 
found no evidence for complement activation in cortical MS 
lesions with evidence for microglia/macrophage activation 
[9]. In our biopsy cohort, terminal complement activation 
was not detectable in gray matter lesions even in actively 
demyelinating cortical lesions with subpial Ig leakage and/
or ongoing monocyte recruitment. In line, the extent of cor-
tical demyelination in Th/+ mice  C1q−/− and Th/+ mice 
 C1q+/+ mice was comparable. Furthermore, the deficiency 
of complement regulatory proteins such as CD59a which 
block the assembly of the MAC on oligodendrocytes did 
not aggravate cortical demyelination in Th/+ mice. Corti-
cal demyelination, however, was diminished by the locally 
applied BB5.1 antibody, which binds to C5 and thus pre-
vents the generation of the cytolytic membrane attack com-
plex by all three complement activation pathways. This sug-
gests that the alternative complement activation pathway 
might also contribute to cortical demyelination as suggested 
Fig. 6  Encephalitogenic T cells are dispensable for subpial but not 
for perivascular demyelination. a, b Quantitative analysis of sub-
pial and perivascular cortical demyelination in 8–18C5 (n = 8) and 
control antibody (n = 9) transferred  RAG1−/− mice analyzed in 
two independent experiments. Data are presented as mean ± SD; 
unpaired t test. c, d Quantitative analysis of subpial and perivascu-
lar cortical demyelination in healthy (n = 4) and diseased OSE mice 
(n = 8) analyzed in two independent experiments. Data are given as 
mean ± SD; Mann–Whitney test. e, f Quantitative analysis of sub-
pial and perivascular cortical demyelination in 2D2 Tc/8-18C5 anti-
body transferred  RAG1−/− mice (n = 6) and OT-II Tc/8-18C5 anti-
body transferred  RAG1−/− mice (n = 12). Representative data of 
two independent experiments are presented as mean ± SD; Mann–
Whitney test. g Assessment of FITC-albumin extravasation by IHC 
in healthy (top) and diseased Th/+ mice (bottom) 24 h after stereo-
tactic cytokine injection into the motor cortex. Dotted lines mark the 
cortical area where FITC-albumin extravasation was quantified. h, 
i Quantification of FITC-albumin extravasation in healthy (n = 4) 




Fig. 7  Inflammatory monocytes are indispensable for cortical demy-
elination in Th/+ mice. a Representative density plots of inflamma-
tory monocytes  (CD45+CD11b+Ly6ChiLy6G-) isolated from the 
cortex of Th/+  CCR2+/+ and Th/+  CCR2−/− mice on day 2 post 
stereotactic injection. b Cortical inflammatory monocytes were quan-
tified by flow cytometry in seven animals/group analyzed in three 
independent experiments and presented as mean ± SD; unpaired t 
test with Welch correction. c Representative IHC for activated micro-
glia/macrophages (Mac-3) in Th/+  CCR2+/+ mice (left) and Th/+ 
 CCR2−/− mice (right). d The number of Mac-3+ intracortical perivas-
cular cuffings was assessed in Th/+  CCR2+/+ and Th/+  CCR2−/− 
mice and presented as mean ± SD; n = 6 mice per group, analyzed in 
two independent experiments; unpaired t test. e–g Quantitative real-
time PCR analysis of monocyte-related cytokines and chemokines in 
the cortex of Th/+  CCR2+/+ (white bars) and Th/+  CCR2−/– mice 
(black bars) on day 2 after stereotactic injection. Results are normal-
ized against GAPDH expression. One representative experiment is 
shown, n = 5 animals per group; Mann–Whitney test. h, i Quanti-
fication of subpial and perivascular cortical demyelination in Th/+ 
 CCR2+/+ (n = 13) and Th/+  CCR2−/− mice (n = 5). Data of three 
independent experiments are shown and expressed as mean ± SD. 
Mann–Whitney test. j Representative flow cytometry dot plots of 
marmoset blood. The monoclonal mouse anti-human CCR2 anti-
body DOC-2 (upper panel right), but not the isotype control antibody 
(upper panel left) binds to marmoset monocytes. Binding of DOC-2 
antibodies to monocytes is lost, if CCR2 is internalized by pretreat-
ment of the cells with CCL2 (1 µg/ml) for 30 min at 37 °C (lower 
panel), demonstrating target specificity. k, l Representative plot for 
titrated humanized DOC-2 antibodies (named DOC-2 Fr) demon-
strating their preserved capability to bind to human (left panel) and 
marmoset monocytes (right panel) after humanization. m Monocyte 
concentrations in the blood of healthy marmosets treated weekly with 
5 mg/kg i.v. of DOC-2 Fr-2
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by previous EAE studies for spinal cord pathology [24]. In 
summary, antibody-opsonization and ADCC are the more 
relevant effector functions of demyelinating antibodies in 
this model of inflammatory cortical demyelination.
In vivo evidence for NK cell-mediated ADCC has been 
provided in NMO animals with pathogenic AQP4 anti-
bodies [43], while most  MOG35–55-induced EAE studies 
focused on the immunoregulatory properties of NK cells 
[19]. Previous studies have also demonstrated that NK 
cells—among others via the activating receptor NKG2D—
can kill oligodendrocytes in vitro independently of patho-
genic antibodies [38, 46]. We detected perivascular NK 
cells in the demyelinated cortex of MS patients. In the 
presence of pathogenic antibodies, NK cells substantially 
contributed to the extent of perivascular, but not subpial 
demyelination in our mouse model. However, as expected, 
the extravasation of NK cells into the cortical parenchyma 
required activated encephalitogenic T cells.
Macrophages are the dominant inflammatory cell type 
in MS white matter lesions [10] and exert crucial effector 
functions in EAE [22]. Recent evidence has been provided 
that  CCR2rfp/+-tagged monocyte-derived macrophages con-
tribute to the initiation of demyelination at the node of Ran-
vier in spinal cord white matter EAE [53] and that  Ly6Chigh 
 CCR2+ inflammatory monocytes licensed by GM-CSF are 
important for EAE induction [13]. The human orthologues 
Fig. 8  Depletion of CCR2+ monocytes in marmosets with EAE 
ameliorates cortical demyelination. a Schematic representation of the 
treatment protocol for marmoset monkeys. b–e Analysis of immune 
cell subpopulations in the blood of marmosets with EAE in response 
to injections of 5 mg/kg DOC-2 Fr2 (twice weekly d14–d28; once 
weekly d28-56). f Representative overview of coronal brain sec-
tions immunostained for MBP (brown). Subpial cortical demyeli-
nated regions (black dotted lines) and perivascular cortical demy-
elinated areas (red lines) are highlighted. g, h The extent of subpial 
and perivascular cortical demyelination was measured on MBP-
immunostained sections of DOC-2 Fr-2 (anti-CCR2, n = 5) and Ctrl-
antibody (n = 5) injected marmosets; Mann–Whitney test. i Clinical 
disease severity of anti-CCR2 or isotype control treated marmosets 
(n = 5/group; *p < 0.05, one sided Mann–Whitney test)
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of mouse inflammatory monocytes which might extrava-
sate and differentiate into inflammatory macrophages in 
the CNS of MS patients are less well defined. We immu-
nostained for CD14 and CCR2 which are expressed by 
classical monocytes in the bloodstream and found evidence 
both for  CD14+  CCR2+ and  CD14+  CCR2− monocytes 
mainly perivascularly in the human demyelinated cortex. 
We interpreted these findings as a recruitment of monocytes 
into the inflamed cortex with  CD14+  CCR2− monocytes 
having either internalized CCR2 in response to ligand bind-
ing [34] or being recruited by additional chemokine recep-
tor/ligand interactions [49]. The former explanation is sup-
ported by cytoplasmic CCR2 immunoreactivity in some of 
the invading monocytes. In line,  CCR2+ cells colocalized 
with Iba-1+ intra- and perivascular monocytes, and less fre-
quently with foamy and phagocytosing KiM1P+ cells. No 
relevant overlap between CCR2 and TMEM119 as well as 
 P2Y12, recently described microglia markers, was observed 
in actively demyelinating MS lesions. Most importantly, 
perivascular monocytes, as well as T cells infiltrating cor-
tical demyelinating lesions could be detected in patients 
with long-standing progressive MS. This suggests that 
invading immune cells are not only involved in the process 
of cortical demyelination in a cohort of MS patients with 
atypical or severe presentation early in the disease, but also 
in patients with chronic MS.
These findings encouraged us to develop a humanized 
anti-CCR2 antibody, which significantly reduced perivas-
cular cortical demyelination and ameliorated the disease 
course in a preclinical model of non-human primate 
EAE, underscoring the relevance of  CCR2+ monocytes 
for inflammatory cortical demyelination. Interestingly, 
we could not demonstrate a significant reduction of sub-
pial cortical demyelination in  CCR2+ monocyte-depleted 
marmosets, which might be due to very low animal num-
bers. Additionally, we might have initiated the deple-
tion of  CCR2+ monocytes too late and some of them 
might already have extravasated into the meninges. The 
expression of activated leukocyte cell adhesion molecule 
(ALCAM) which participates in the multi-step extrava-
sation process of monocytes across the BBB, is signifi-
cantly higher in human meningeal endothelial cells than 
in brain endothelial cells [25].
In considering the clinical translation of our experi-
mental findings for the treatment of progressive MS, we 
acknowledge a number of limitations. We initiated the 
cortical demyelination in the Th/+ mouse by the intra-
cortical injections of TNFα and IFNγ. Although both 
Fig. 9  Differential involvement 
of immune effector mecha-
nisms in perivascular type 2 
and subpial type 3 cortical 
demyelination. Whereas subpial 
cortical demyelination occurs 
in the absence of an adaptive 
immune response, executed 
by the concerted action of 
pro-inflammatory cytokines, 
demyelinating antibodies, and 
 CCR2+ monocytes, activated 
encephalitogenic T cells and 





cytokines are increased in the CSF of MS patients with 
cortical demyelination, the inflammatory CSF milieu in 
MS is clearly more complex [14]. The mouse model, 
as well as the marmoset EAE model relied on the pres-
ence of demyelinating MOG-specific antibodies, which 
are rarely detected in MS patients [48]. Finally, the quite 
rapid resolution of cortical inflammation and demyelina-
tion seen in animal models even after multiple intracorti-
cal cytokine injections [44] and the relative lack of neu-
roaxonal damage are in contrast to the widespread and 
ongoing cortical demyelination and the extent of neu-
roaxonal loss seen in MS. Irrespective of the shortcom-
ings of all currently available experimental models for 
MS, the success of a number of treatment strategies for 
the human disease, which were established first in ani-
mal models, such as, e.g., natalizumab [42, 54], demon-
strate that shared and pathogenetically relevant mecha-
nisms exist in our experimental models and the human 
disease.
In conclusion, cortical demyelination in general and 
subpial demyelination in particular are highly characteris-
tic features of progressive MS. Our data indicate that dis-
tinct local barrier properties may underlie the differential 
tissue vulnerability in the cerebral cortex. Furthermore, 
we reveal that only a limited number of effector mecha-
nisms are required for subpial demyelination in a novel 
mouse model of cortical inflammatory demyelination. 
The limited necessity for peripheral adaptive immune 
activation for the pathogenesis of subpial (type 3) demy-
elination may in part explain the difficulties encountered 
in therapeutically targeting the ongoing tissue damage in 
the progressive phase of the disease. Importantly,  CCR2+ 
monocytes play a central role in the pathogenesis of cor-
tical demyelination and their depletion proves a novel 
therapeutic concept to ameliorate cortical pathology.
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